FTC blocks Illumina's PacBio buyout

By LabPulse.com staff writers

December 18, 2019 -- The U.S. Federal Trade Commission (FTC) is blocking Illumina's planned $1.2 billion acquisition of Pacific Biosciences of California (PacBio) on the grounds that the deal would be anticompetitive.

In a press statement, the FTC explained that it filed an administrative complaint charging that Illumina is pursuing the acquisition to "unlawfully maintain its monopoly" in the U.S. market for next-generation sequencing "by extinguishing PacBio as a nascent competitive threat."

PacBio pioneered long-read sequencing technology and has improved the accuracy of its products and also lowered costs, the agency noted.

"Customers have already switched some sequencing volume from Illumina to PacBio for certain use cases and applications, and PacBio is poised to take increasing sequencing volume from Illumina in the future," the FTC said.

Following the filing of an administrative complaint, charges are reviewed by an administrative law judge in a formal hearing. In the meantime, the agency is seeking a temporary restraining order to block action on the deal.

Labs gear up to meet demand for genetic testing
Genetic testing and gene sequencing represent a paradigm shift in testing, but labs still have some time to develop a winning strategy for adapting to...
ArcherDX partners with Illumina on companion tests
Diagnostics company ArcherDX is partnering with Illumina to develop its next-generation sequencing companion tests for oncology indications.
Lexent Bio partners on NGS with Illumina
San Francisco-based Lexent Bio has signed a nonexclusive deal to adapt its lead investigational Confera Dx next-generation sequencing (NGS) cancer test...
Qiagen tie-up with Illumina is a sign of the IVD times
Qiagen and Illumina have signed a 15-year strategic partnership on IVD tests that will take advantage of their respective strengths in companion diagnostics...
Adaptive partners with Illumina for IVD test kits
Adaptive Biotechnologies is partnering with Illumina to bring to market IVD test kits for Adaptive's current and future portfolio of immunodiagnostics...

Copyright © 2019 LabPulse.com

Last Updated np 12/18/2019 10:25:07 AM